Long acting GLP-1 receptor agonist (injectable)
Semaglutide 8 mg injection once weekly
SEMA_SC_8MG_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.53 (-1.05 to -0.02) | 0.76 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -7.61 (-10.38 to -4.92) | 0.89 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | MD -1.82 (-8.52 to 5.12) | 0.82 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.21 (0.00 to 5.35) | 0.75 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.61 (0.10 to 2.65) | 0.65 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 10.85 (3.14 to 46.25) | 0.08 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.86 (2.28 to 10.27) | 0.26 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.28 (1.70 to 10.87) | 0.35 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.70 (1.72 to 8.07) | 0.17 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 6.13 (1.69 to 24.14) | 0.12 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 11.13 (2.33 to 73.87) | 0.11 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.19 (0.07 to 15.37) | 0.48 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.31 (0.14 to 10.63) | 0.38 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.40 (0.00 to 16.84) | 0.66 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.27 (0.00 to 7.76) | 0.65 |